- Home
- RCS vs SLN Comparison
RCS vs SLN Comparison
Compare RCS & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | SLN |
|---|---|---|
| Founded | 1994 | 1994 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.2M | 318.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCS | SLN |
|---|---|---|
| Price | $5.72 | $4.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 191.0K | ★ 203.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $1.97 |
| 52 Week High | $8.00 | $7.78 |
Technical Indicators
Market Signals| Indicator | RCS | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 47.85 |
| Support Level | $5.72 | $4.38 |
| Resistance Level | $6.03 | $4.97 |
| Average True Range (ATR) | 0.13 | 0.40 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 12.12 | 79.20 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.